Paediatric schistosomiasis: What we know and what we need to know. 2018

Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, University of Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom.

Schistosomiasis affects over 200 million people worldwide, most of whom are children. Research and control strategies directed at preschool-aged children (PSAC), i.e., ≤5 years old, have lagged behind those in older children and adults. With the recent WHO revision of the schistosomiasis treatment guidelines to include PSAC, and the recognition of gaps in our current knowledge on the disease and its treatment in this age group, there is now a concerted effort to address these shortcomings. Global and national schistosome control strategies are yet to include PSAC in treatment schedules. Maximum impact of schistosome treatment programmes will be realised through effective treatment of PSAC. In this review, we (i) discuss the current knowledge on the dynamics and consequences of paediatric schistosomiasis and (ii) identify knowledge and policy gaps relevant to these areas and to the successful control of schistosome infection and disease in this age group. Herein, we highlight risk factors, immune mechanisms, pathology, and optimal timing for screening, diagnosis, and treatment of paediatric schistosomiasis. We also discuss the tools required for treating schistosomiasis in PSAC and strategies for accessing them for treatment.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D009017 Morbidity The proportion of patients with a particular disease during a given year per given unit of population. Morbidities
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012547 Schistosoma A genus of trematode flukes belonging to the family Schistosomatidae. There are over a dozen species. These parasites are found in man and other mammals. Snails are the intermediate hosts. Bilharzia,Bilharzias,Schistosomas
D012552 Schistosomiasis Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States. Bilharziasis,Katayama Fever,Schistoma Infection,Bilharziases,Fever, Katayama,Infection, Schistoma,Infections, Schistoma,Schistoma Infections,Schistosomiases
D017053 Infection Control Programs of disease surveillance, generally within health care facilities, designed to investigate, prevent, and control the spread of infections and their causative microorganisms. Control, Infection

Related Publications

Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
November 2018, Veterinary sciences,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
July 2019, Current opinion in urology,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
June 2020, The Journal of urology,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
November 2013, Immunology and allergy clinics of North America,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
January 2022, The European respiratory journal,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
January 2016, The American psychologist,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
January 2020, Porto biomedical journal,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
January 2009, Journal of cardiopulmonary rehabilitation and prevention,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
January 2015, Critical reviews in food science and nutrition,
Derick N M Osakunor, and Mark E J Woolhouse, and Francisca Mutapi
February 2017, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Copied contents to your clipboard!